^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PRKCA mutation

    i
    Other names: PRKCA, Protein Kinase C Alpha, Protein Kinase C Alpha Type, PKC-Alpha, PRKACA, PKC-A, PKCA, Aging-Associated Gene 6, Protein Kinase C, Alpha, PKCalpha, PKCI+/-, AAG6
    Entrez ID:
    5578
    over2years
    Attempting to Solve the Pigmented Epithelioid Melanocytoma (PEM) Conundrum: PRKAR1A Inactivation Can Occur in Different Genetic Backgrounds (Common, Blue, and Spitz Subgroups) With Variation in Their Clinicopathologic Characteristics. (PubMed, Am J Surg Pathol)
    These results could potentially shift the concept of PRKAR1A-inactivated melanocytoma, changing from a rather unified model to a more complex one, including genetic subgroup variations with clinical and morphologic specificities. The genetic background of PRKAR1A-inactivated melanocytic tumors should be systematically explored to better understand the extent and clinical behavior of these complex lesions.
    Journal
    |
    BRAF (B-raf proto-oncogene) • HRAS (Harvey rat sarcoma viral oncogene homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • GNAQ (G Protein Subunit Alpha Q) • CYSLTR2 (Cysteinyl Leukotriene Receptor 2) • MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8) • PRKAR1A (Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha) • PRKCA (Protein Kinase C Alpha)
    |
    BRAF V600E • BRAF V600 • GNAQ Q209L • HRAS mutation • CYSLTR2 L129Q • PRKCA mutation
    over3years
    Chordoid glioma: a clinicopathological study (PubMed, Zhonghua Bing Li Xue Za Zhi)
    Chordoid gliomas have relatively distinguishing clinical and histopathological features. PRKCA gene mutation in chordoid gliomas can be considered as a biomarker for the diagnosis and differential diagnosis of chordoid gliomas, and may provide a direction for future targeted therapy.
    Clinical • Retrospective data • Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CD34 (CD34 molecule) • NKX2-1 (NK2 Homeobox 1) • VIM (Vimentin) • PRKCA (Protein Kinase C Alpha) • GFAP (Glial Fibrillary Acidic Protein)
    |
    IDH2 mutation • VIM expression • IDH2 R172 • PRKCA mutation
    4years
    PRKCA D463H Mutation in Chordoid Glioma of the Third Ventricle: A Cohort of 16 Cases, Including Two Cases Harboring BRAFV600E Mutation. (PubMed, J Neuropathol Exp Neurol)
    Eleven were alive at the most recent follow-up (range: 2-58 months). These data indicate that PRKCA mutation was a good diagnostic marker for CG and additionally suggest that histiocyte-like features can be present in CG in association with BRAF mutations.
    Clinical • Journal
    |
    BRAF (B-raf proto-oncogene) • PRKCA (Protein Kinase C Alpha)
    |
    BRAF V600E • BRAF V600 • PRKCA mutation
    over4years
    RNA-Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights. (PubMed, J Clin Endocrinol Metab)
    MACS-CPAs and EIAs showed a similar transcriptome profile, independently of the genetic background, whereas most CS-CPAs clustered together. Still unrevealed molecular alterations in the cAMP/PKA or Wnt/beta catenin pathways might be involved in the pathogenesis of adrenocortical tumors.
    Journal
    |
    GNAS (GNAS Complex Locus) • PRKCA (Protein Kinase C Alpha)
    |
    PRKCA mutation